[ad_1]
Healthcare firm Vertex Prescribed drugs Integrated (NASDAQ: VRTX) on Monday reported a rise in revenues for the third quarter of 2023. The corporate additionally offered steerage for fiscal 2023.
September-quarter earnings, adjusted for particular gadgets, moved as much as $4.08 per share from $4.01 per share in the identical interval of 2022. Unadjusted revenue was $1.04 billion or $3.97 per share, vs. $930.5 million or $3.59 per share a yr earlier.
The corporate mentioned that third-quarter revenues elevated to $2.48 billion from $2.33 billion within the year-ago interval. For the entire of fiscal 2023, the administration expects whole product revenues to be within the vary of $9.85 billion.
Prior Efficiency
[ad_2]
Source link
